Nucleic acid sensing receptors in systemic lupus erythematosus: Development of novel DNA- and/or RNA-like analogues for treating lupus

Clinical and Experimental Immunology

Volumn 161, Issue 2, 2010, Pages 208-222

  Lenert, P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

HIN 200; HMGB1; systemic lupus erythematosus; Toll like receptors 7 and 9

Indexed keywords

CASPASE INHIBITOR; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE; DNA; DNA BINDING PROTEIN; DNA DIRECTED RNA POLYMERASE III; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; NUCLEIC ACID; NUCLEOPROTEIN; OLIGONUCLEOTIDE; PROTEIN AIM2; PROTEIN MDA5; PROTEIN P202; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; Z DNA BINDING PROTEIN 1;

AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CYTOSOL; DENDRITIC CELL; DNA VIRUS; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA VIRUS; SENSOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OLIGONUCLEOTIDES; RNA-BINDING PROTEINS; TOLL-LIKE RECEPTORS;

EID: 77954647644     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04176.x     Document Type: Review

References (180)

1. Sheriff A, Gaipl US, Voll RE, Kalden JR, Herrmann M. Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am 2004 30 : 505 27.
2. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003 100 : 2610 15.
3. Alarcón-Segovia D, Alarcón-Riquelme ME, Cardiel MH et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005 52 : 1138 47.
4. Graham RR, Kyogoku C, Sigurdsson S et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007 104 : 6758 63.
5. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008 40 : 204 10.
6. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009 10 : 373 9.
7. Javierre BM, Fernandez AF, Richter J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 2010 20 : 170 9.
8. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990 33 : 1665 73.
9. Corvetta A, Della Bitta R, Luchetti MM, Pomponio G. 5-Methylcytosine content of DNA in blood, synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases. J Chromatogr 1991 566 : 481 91.
10. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988 140 : 2197 200.
11. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998 12 : 1255 65.
12. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005 11 : 85 9.
13. Carpenter DF, Steinberg AD, Schur PH, Talal N. The pathogenesis of autoimmunity in New Zealand mice. II. Acceleration of glomerulonephritis by polyinosinic-polycytidylic acid. Lab Invest 1970 23 : 628 34.
14. Pawar RD, Patole PS, Zecher D et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006 17 : 141 9.
15. Hasegawa K, Hayashi T. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB × NZWF1 mice. Lupus 2003 12 : 838 45.
16. Anders HJ, Vielhauer V, Eis V et al. Activation of Toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004 18 : 534 6.
17. Lian ZX, Kikuchi K, Yang GX, Ansari AA, Ikehara S, Gerswin ME. Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J Immunol 2004 173 : 5283 9.
18. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000 408 : 740 5.
19. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004 303 : 1529 31.
20. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004 303 : 1526 9.
21. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004 101 : 5598 603.
22. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001 413 : 732 8.
23. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005 202 : 321 31.
24. Hannum LG, Ni D, Haberman AM, Weigert MG, Shlomchik MJ. A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J Exp Med 1996 184 : 1269 78.
25. Monestier M, Kotzin BL. Antibodies to histones in systemic lupus erythematosus and drug-induced lupus. Rheum Dis Clin North Am 1992 18 : 415 36.
26. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Schlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002 416 : 603 7.
27. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003 19 : 837 47.
28. Uccellini MB, Busconi L, Green NM et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol 2008 181 : 5875 84.
29. Lau CM, Broughton C, Tabor AS et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005 202 : 1171 7.
30. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses toDNA-containing antigens. Immunity 2008 28 : 799 809.
31. O'Neill SK, Veselits ML, Zhang M et al. Endocytic sequestration of the B cell antigen receptor and Toll-like receptor 9 in anergic cells. Proc Natl Acad Sci USA 2009 106 : 6262 7.
32. Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation bychromatin-immunoglobulin G complexes. J Exp Med 2004 199 : 1631 40.
33. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005 115 : 407 17.
34. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006 25 : 417 28.
35. Lee PY, Kumagai Y, Li Y, Takeuchi O et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008 205 : 2995 3006.
36. Savarese E, Steinberg C, Pawar RD et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008 58 : 1107 15.
37. Pan ZJ, Maier S, Schwarz K et al. TLR7 modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells. Ann Rheum Dis 2009 doi:10.1136/ard.2009.108282.
38. Deane JA, Pisitkun P, Barrett RS et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007 27 : 801 10.
39. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006 312 : 1669 72.
40. Subramanian S, Tus K, Li QZ et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006 103 : 9970 5.
41. Fairhurst AM, Hwang SH, Wang A et al. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur J Immunol 2008 38 : 1971 8.
42. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006 203 : 553 61.
43. Richez C, Yasuda K, Bonegio RG et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol 2010 184 : 796 806.
44. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 2002 195 : 1167 74.
45. Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 2006 54 : 336 42.
46. Yu P, Wellmann U, Kunder S et al. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int Immunol 2006 18 : 1211 19.
47. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005 174 : 2429 34.
48. Lenert P, Brummel R, Field EH, Ashman RF. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005 25 : 29 40.
49. Santiago-Raber ML, Dunand-Sauthier I, Wu T et al. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun 2009 doi:10.1016/j.jaut.2009.11.001.
50. Patole PS, Gröne HJ, Segerer S et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005 16 : 1326 38.
51. Kono DH, Haraldsson MK, Lawson BR et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA 2009 106 : 12061 6.
52. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008 452 : 234 8.
53. Tabeta K, Hoebe K, Janssen EM et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006 7 : 156 64.
54. Fukui R, Saitoh S, Matsumoto F et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med 2009 206 : 1339 50.
55. Papadimitraki ED, Tzardi M, Bertsias G, Sotsiou E, Boumpas DT. Glomerular expression of Toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus 2009 18 : 831 5.
56. Zorro S, Arias M, Riaño F et al. Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus 2009 18 : 718 26.
57. Wu O, Chen GP, Chen H et al. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 2009 214 : 392 402.
58. Komatsuda A, Wakui H, Iwamoto K et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008 152 : 482 7.
59. Visentini M, Conti V, Cagliuso M et al. Regression of systemic lupus erythematosus after development of an acquired Toll-like receptor signaling defect and antibody deficiency. Arthritis Rheum 2009 60 : 2767 71.
60. Xu CJ, Zhang WH, Pan HF, Li XP, Xu JH, Ye DQ. Association study of a single nucleotide polymorphism in the exon 2 region of Toll-like receptor 9 (TLR9) gene with susceptibility to systemic lupus erythematosus among Chinese. Mol Biol Rep 2009 36 : 2245 8.
61. Sánchez E, Callejas-Rubio JL, Sabio JM et al. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus. Clin Exp Rheumatol 2009 27 : 267 71.
62. Spies B, Hochrein H, Vabulas M et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003 171 : 5908 12.
63. Babiuk S, Mookherjee N, Pontarollo R et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 2004 113 : 114 20.
64. Cortez-Gonzalez X, Pellicciotta I, Gerloni M et al. TLR9-independent activation of B lymphocytes by bacterial DNA. DNA Cell Biol 2006 25 : 253 61.
65. Ishii KJ, Kawagoe T, Koyama S et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008 451 : 725 9.
66. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J Exp Med 2005 202 : 1333 9.
67. Yoshida H, Okabe Y, Kawane K, Fukuyama H, Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol 2005 6 : 49 56.
68. Choubey D, Panchanathan R. Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol Lett 2008 119 : 32 41.
69. Mondini M, Vidali M, Airò P et al. Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. Ann NY Acad Sci 2007 1110 : 47 56.
70. Song LL, Ponomareva L, Shen H, Duan X, Alimirah F, Choubey D. Interferon-inducible IFI16, a negative regulator of cell growth, down-regulates expression of human telomerase reverse transcriptase (hTERT) gene. PLoS One 2010 5 : e8569.
71. Jørgensen TN, Gubbels MR, Kotzin BL. Links between type I interferons and the genetic basis of disease in mouse lupus. Autoimmunity 2003 36 : 491 502.
72. Roberts TL, Idris A, Dunn JA et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009 323 : 1057 60.
73. Hornung V, Ablasser A, Charrel-Dennis M et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009 458 : 514 18.
74. Wang H, Chatterjee G, Meyer JJ et al. Characteristics of three homologous 202 genes (Ifi202a, Ifi202b, and Ifi202c) from the murine interferon- activatable gene 200 cluster. Genomics 1999 60 : 281 94.
75. Gubbels Bupp MR, Li M, Pashine A, Aud D, Peng SL. The candidate lupus susceptibility gene Ifi202a is largely dispensable for B-cell function. Rheumatology (Oxf) 2008 47 : 103 4.
76. Santiago-Raber ML, Laporte C, Reininger L, Izui S. Genetic basis of murine lupus. Autoimmun Rev 2004 3 : 33 9.
77. Teramoto K, Negoro N, Kitamoto K et al. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharmacol Sci 2008 106 : 56 67.
78. Kimkong I, Avihingsanon Y, Hirankarn N. Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus 2009 18 : 1066 72.
79. Peterson KS, Huang JF, Zhu J et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004 113 : 1722 33.
80. Yamauchi M, Hashimoto M, Ichiyama K et al. Ifi202, an IFN-inducible candidate gene for lupus susceptibility in NZB/W F1 mice, is a positive regulator for NF-kappaB activation in dendritic cells. Int Immunol 2007 19 : 935 42.
81. Hueber W, Zeng D, Strober S, Utz PJ. Interferon-alpha-inducible proteins are novel autoantigens in murine lupus. Arthritis Rheum 2004 50 : 3239 49.
82. Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007 448 : 501 5.
83. Wang Z, Choi MK, Ban T et al. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008 105 : 5477 82.
84. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA 2004 101 : 233 8.
85. Rebsamen M, Heinz LX, Meylan E et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep 2009 10 : 916 22.
86. Kaiser WJ, Upton JW, Mocarski ES. Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. J Immunol 2008 181 : 6427 34.
87. Lippmann J, Rothenburg S, Deigendesch N et al. IFN beta responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI). Cell Microbiol 2008 10 : 2579 88.
88. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007 220 : 35 46.
89. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008 10 : 209.
90. Ivanov S, Dragoi AM, Wang X et al. A novel role for HMGB1 in TLR9 mediated inflammatory responses to CpG-DNA. Blood 2007 110 : 1970 81.
91. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989 243 : 1056 9.
92. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007 8 : 487 96.
93. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006 7 : 774 8.
94. Avalos AM, Kiefer K, Tian J et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2010 43 : 103 10.
95. Bell CW, Jiang W, Reich CF III., Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006 291 : C1318 25.
96. Gauley J, Pisetsky DS. The translocation of HMGB1 during cell activation and cell death. Autoimmunity 2009 42 : 299 301.
97. Urbonaviciute V, Fürnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008 205 : 3007 18.
98. Popovic K, Ek M, Espinosa A et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005 52 : 3639 45.
99. Ayer LM, Rubin RL, Dixon GH, Fritzler MJ. Antibodies to HMG proteins in patients with drug-induced autoimmunity. Arthritis Rheum 1994 37 : 98 103.
100. Jiang W, Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 2008 67 : 727 8.
101. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA : dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009 10 : 1065 72.
102. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009 138 : 576 91.
103. Ishii KJ, Coban C, Kato H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006 7 : 40 8.
104. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004 5 : 730 7.
105. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 2002 99 : 637 42.
106. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006 441 : 101 5.
107. Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008 205 : 1601 10.
108. Allam R, Pawar RD, Kulkarni OP et al. Viral 5′-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol 2008 38 : 3487 98.
109. Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001 22 : 427 31.
110. Crow MK, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheum 2004 16 : 541 7.
111. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003 36 : 511 18.
112. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979 301 : 5 8.
113. Bengtsson AA, Sturfelt G, Truedsson L et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000 9 : 664 71.
114. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003 5 : 279 87.
115. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 97 : 711 23.
116. Feng X, Wu H, Grossman JM et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006 54 : 2951 62.
117. Petri M, Singh S, Tesfasyone H et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009 18 : 980 9.
118. Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens JP, Chaperot L, Plumas J. TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood 2009 114 : 1794 802.
119. Takauji R, Iho S, Takatsuka H et al. CpG-DNA-induced IFN-alpha production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. J Leukoc Biol 2002 72 : 1011 19.
120. Yasuda K, Richez C, Uccellini MB et al. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol 2009 183 : 3109 17.
121. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005 174 : 2499 506.
122. Santiago-Raber ML, Baccala R, Haraldsson KM et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003 197 : 777 88.
123. Agrawal H, Jacob N, Carreras E et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009 183 : 6021 9.
124. Green NM, Laws A, Kiefer K et al. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol 2009 183 : 1569 76.
125. Brummel R, Roberts TL, Stacey KJ, Lenert P. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Eur J Immunol 2006 36 : 1951 62.
126. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001 294 : 1540 3.
127. Yao Y, Richman L, Higgs BW et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009 60 : 1785 96.
128. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008 17 : 394 9.
129. Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998 7 : 80 5.
130. Halpern MD, Pisetsky DS. In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology 1995 29 : 47 52.
131. Pisetsky DS, Reich CF. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol 2000 96 : 198 204.
132. Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol 2002 72 : 1154 63.
133. Krieg AM, Wu T, Weeratna R et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998 95 : 12631 6.
134. Chen Y, Lenert P, Weeratna R et al. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther 2001 8 : 1024 32.
135. Lenert P, Stunz L, Yi AK, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kB activation. Antisense Nucleic Acid Drug Dev 2001 11 : 247 56.
136. Lenert P, Yi AK, Krieg AM, Stunz LL, Ashman RF. Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. Antisense Nucleic Acid Drug Dev 2003 13 : 143 50.
137. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003 171 : 1393 400.
138. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A[D]-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003 22 : 621 31.
139. Ashman RF, Goeken JA, Drahos J, Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005 17 : 411 20.
140. Sun R, Sun L, Bao M et al. A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways. Clin Immunol 2010 134 : 262 76.
141. Stunz LL, Lenert P, Peckham D et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol 2002 32 : 1212 22.
142. Lenert P. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 2005 140 : 1 10.
143. Duramad O, Fearon KL, Chang B et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005 174 : 5193 200.
144. Ashman RF, Lenert P. Structural requirements and applications of inhibitory oligodeoxyribonucleotides. Immunol Res 2007 39 : 4 14.
145. Haas T, Metzger J, Schmitz F et al. The DNA sugar backbone 2′ deoxyribose determines Toll-like receptor 9 activation. Immunity 2008 28 : 315 23.
146. Patole PS, Zecher D, Pawar RD, Grone H-J, Schlondorff D, Anders H-J. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005 16 : 3273 80.
147. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005 202 : 1131 9.
148. Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 2008 123 : 118 28.
149. Pearson AM, Rich A, Krieger M. Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices. J Biol Chem 1993 268 : 3546 54.
150. lpr/lpr mice in vivo. Arthritis Res Ther 2009 11 : R79.
151. Lenert P. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006 8 : R203.
152. Honda K, Ohba Y, Yannai H et al. Spatiotemporal regulation of MyD88-IRF-7 signaling for robust type-I interferon induction. Nature 2005 434 : 1035 40.
153. Guiducci C, Ott G, Chan JH et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006 203 : 1999 2008.
154. Avalos AM, Latz E, Mousseau B et al. Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides. J Immunol 2009 183 : 6262 8.
155. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naïve B cells and constitutive expression in memory B cells. Blood 2003 102 : 956 63.
156. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006 36 : 810 16.
157. Poeck H, Wagner M, Battiany J et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004 103 : 3058 64.
158. Busconi L, Bauer JW, Tumang JR et al. Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J Immunol 2007 179 : 7397 405.
159. Klinman DM, Tross D, Klaschik S, Shirota H, Sato T. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann NY Acad Sci 2009 1175 : 80 8.
160. Shirota H, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma and IL-12-mediated signaling. J Immunol 2004 173 : 5002 7.
161. Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum 2003 48 : 1701 7.
162. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum 2005 52 : 651 8.
163. Sato T, Shimosato T, Alvord WG, Klinman DM. Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation. J Immunol 2008 180 : 7648 54.
164. Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 2005 174 : 4579 83.
165. Jing N, Li Y, Xu X et al. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 2003 22 : 685 96.
166. Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of signal transducers and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004 64 : 6603 9.
167. Hanakahi LA, Sun H, Maizels N. High affinity interactions of nucleolin with G-G-aspired rDNA. J Biol Chem 1999 274 : 15908 12.
168. Bianchi A, de Lange T. Ku binds telomeric DNA in vitro. J Biol Chem 1999 274 : 21223 7.
169. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007 37 : 3582 6.
170. Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Treatment with a Toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice. Autoimmunity 2010 43 : 140 55.
171. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation medicated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005 202 : 1575 85.
172. Jurk M, Kritzler A, Schulte B et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 2006 36 : 1815 26.
173. Gorden KK, Qiu X, Batiste JJ, Wightman PP, Vasilakos JP, Alkan SS. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 2006 177 : 8164 70.
174. Wang D, Bhagat L, Yu D et al. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem 2009 52 : 551 8.
175. Trieu A, Roberts TL, Dunn JA, Sweet MJ, Stacey KJ. DNA motifs suppressing TLR9 responses. Crit Rev Immunol 2006 26 : 527 44.
176. Ewald SE, Lee BL, Lau L et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008 456 : 658 62.
177. Sepulveda FE, Maschalidi S, Colisson R et al. Critical role for asparagine endopeptidase in endocytic toll-like receptor signaling in dendritic cells. Immunity 2009 31 : 737 48.
178. Latz E, Verma A, Visintin A et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007 8 : 772 9.
179. Yao M, Liu X, Li D, Chen T, Cai Z, Cao X. Late endosome/lysosome- localized Rab7b suppresses TLR9-initiated proinflammatory cytokine and type I IFN production in macrophages. J Immunol 2009 183 : 1751 8.
180. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007 18 : 1721 31.